-
1
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
Published 2025-02-01“…Blood Cancer Journal…”
Get full text
Article -
2
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax
Published 2025-02-01“…Blood Cancer Journal…”
Get full text
Article -
3
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
Published 2025-02-01“…Blood Cancer Journal…”
Get full text
Article -
4
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Published 2025-02-01“…Blood Cancer Journal…”
Get full text
Article -
5
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell ly...
Published 2024-11-01“…Blood Cancer Journal…”
Get full text
Article -
6
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry
Published 2025-02-01“…Blood Cancer Journal…”
Get full text
Article -
7
Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
Published 2025-02-01“…Blood Cancer Journal…”
Get full text
Article -
8
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target
Published 2024-05-01“…Blood Cancer Journal…”
Get full text
Article -
9
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Published 2025-02-01“…Blood Cancer Journal…”
Get full text
Article -
10
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
Published 2025-02-01“…Blood Cancer Journal…”
Get full text
Article